Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average recommendation of “Buy” from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. Fifteen research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $244.3571.

ASND has been the topic of a number of analyst reports. Wedbush lifted their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Wells Fargo & Company reiterated an “overweight” rating and issued a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 target price on the stock.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $194.62 on Tuesday. The firm’s fifty day moving average price is $185.73 and its 200-day moving average price is $169.99. The stock has a market cap of $11.91 billion, a P/E ratio of -37.72 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $208.16.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Ascendis Pharma A/S by 0.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock worth $2,103,000 after acquiring an additional 73 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth $897,000. Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth $206,000. Soleus Capital Management L.P. grew its holdings in Ascendis Pharma A/S by 51.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 85,000 shares of the biotechnology company’s stock worth $14,671,000 after acquiring an additional 28,700 shares during the last quarter. Finally, Vestal Point Capital LP boosted its stake in shares of Ascendis Pharma A/S by 33.2% during the 2nd quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock valued at $34,520,000 after purchasing an additional 49,858 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.